Olgram’s €1,5 Million Funding

Dechert advised Olgram on the deal. Olgram, a French biotech company that develops algae-based anti-infectives, completed its €1.5 million fundraising. The investors include bpifrance, the Brittany...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Biomunex Pharmaceuticals’ Agreement with Onward Therapeutics and Series A Fundraising

Dechert advised Biomunex Pharmaceuticals on the deal. Biomunex Pharmaceuticals, a French biopharmaceutical company, closed a strategic exclusive worldwide license and co-development agreement with Onward Therapeutics SA...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here